These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15059702)

  • 1. Dropout rates for intent-to-treat and per protocol analyses.
    Stewart WC; Jackson AL; Jenkins JN
    Am J Ophthalmol; 2004 Apr; 137(4):639-45. PubMed ID: 15059702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjusting sample size for anticipated dropouts in clinical trials.
    Overall JE; Shobaki G; Shivakumar C; Steele J
    Psychopharmacol Bull; 1998; 34(1):25-33. PubMed ID: 9564195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
    Katz LJ; Simmons ST; Craven ER
    Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat.
    Matilde Sanchez M; Chen X
    Stat Med; 2006 Apr; 25(7):1169-81. PubMed ID: 16397861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation.
    Greenland S; Lanes S; Jara M
    Clin Trials; 2008; 5(1):5-13. PubMed ID: 18283074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results?
    Parrish RK
    Curr Opin Ophthalmol; 2006 Apr; 17(2):138-41. PubMed ID: 16552248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
    Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
    J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to control measurement variation in estimating the mean intraocular pressure reducing effect at a specific point in time.
    Hedman K; Taube A
    Contemp Clin Trials; 2005 Jun; 26(3):402-15. PubMed ID: 15911474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
    Bengtsson B; Leske MC; Hyman L; Heijl A;
    Ophthalmology; 2007 Feb; 114(2):205-9. PubMed ID: 17097736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.
    Day DG; Sharpe ED; Atkinson MJ; Stewart JA; Stewart WC
    Eye (Lond); 2006 May; 20(5):583-90. PubMed ID: 15933751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
    Gomeni R; Lavergne A; Merlo-Pich E
    Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
    Aptel F; Cucherat M; Denis P
    J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma.
    Nagar M; Ogunyomade A; O'Brart DP; Howes F; Marshall J
    Br J Ophthalmol; 2005 Nov; 89(11):1413-7. PubMed ID: 16234442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
    Ito K; Goto R; Matsunaga K; Sugimoto K; Uji Y
    Jpn J Ophthalmol; 2004; 48(3):276-80. PubMed ID: 15175922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.